The metabolism of arachidonic acid to an antiaggregatory compound in isolated lungs of fetal and neonatal rabbits.
The developmental pattern of fetal and neonatal rabbit lungs to generate an antiaggregatory compound from arachidonic acid (AA) was studied in isolated rabbit lungs, which were perfused with Krebs bicarbonate buffer. The antiaggregatory effect of the nonrecirculating perfusion effluent was tested by adding a small portion of the effluent to human platelet rich plasma (PRP) in a Born-type aggregometer before the aggregation was induced by ADP. The production of an antiaggregatory compound was minimal, when exogenous AA was not infused into the pulmonary circulation. When arachidonate (40 nmol/min) was infused into the pulmonary circulation of rabbits which were 1 day or 1 week old, the perfusion effluent significantly inhibited the ADP induced aggregation of PRP. Perfused lungs from fetal rabbits (gestation age 28-31 days) formed also an antiaggregatory compound from AA, but the antiaggregatory effect was not as great as 1 day after birth. It seems that neonatal rabbit lungs metabolize AA more to an antiaggregatory compound than late fetal lungs. The fact that the AA induced production of an antiaggregatory compound is inhibited by simultaneous infusion of indomethacin favours the hypothesis that this antiaggregatory compound could be PGI2.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn / Q000378:metabolism*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D004355:Drug Stability; D011464:Epoprostenol / Q000378:metabolism; D007213:Indomethacin / Q000494:pharmacology; D008168:Lung / Q000196:embryology* / Q000254:growth & development / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits
D001095:Arachidonic Acids; D016718:Arachidonic Acid; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D007213:Indomethacin